Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360423 | 1.00 | FAAH (0.52) | FAAHLTB4RPTPN1SOAT1CYP4F2 | |
| SCHEMBL9522369 | 0.88 | LTB4R (0.44) | FAAHLTB4RPTPN1 | |
| SCHEMBL8987216 | 0.88 | ALDH2 (0.46) | FAAHLTB4RPTPN1TBXAS1CYSLTR2 | |
| SCHEMBL8987100 | 0.88 | ALDH2 (0.46) | FAAHLTB4RPTPN1TBXAS1CYSLTR2 | |
| SCHEMBL5407468 | 0.85 | LTB4R (0.62) | LTB4RFABP3FABP4 | |
| SCHEMBL8987198 | 0.83 | FAAH (0.51) | FAAHLTB4RCYP4F2CYP4A11TBXAS1 | |
| SCHEMBL5365520 | 0.82 | LTB4R (0.49) | LTB4RSOAT1FABP3FABP4 | |
| SCHEMBL8987210 | 0.81 | LTB4R (0.58) | FAAHLTB4R | |
| SCHEMBL8987412 | 0.81 | LTB4R (0.58) | FAAHLTB4R | |
| SCHEMBL27397039 | 0.80 | KDM4E (0.56) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271266-B2 | Substituted 2,3-diphenyl pyridines | MERCK & CO., INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20050182103-A1 | Substituted 2,3-diphenyl pyridines | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| EP-1492784-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082191-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| US-5492915-A | ANTIINFLAMMATORY AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-20 | — | — | US | disclosed |
| US-5366982-A | Antiinflammatory agents or antihistamines | RHONE-POULENC RORER S.A. (FR) | 1994-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182103-A1 | Substituted 2,3-diphenyl pyridines | CNR1, CNR2, MAG | FAAH 5/4885LTB4R 688/4885PTPN1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.